BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 30292627)

  • 1. Is immunohistochemical staining for β-catenin the definitive pathological diagnostic tool for desmoid-type fibromatosis? A multi-institutional study.
    Koike H; Nishida Y; Kohno K; Shimoyama Y; Motoi T; Hamada S; Kawai A; Ogose A; Ozaki T; Kunisada T; Matsumoto Y; Matsunobu T; Ae K; Gokita T; Sakai T; Shimizu K; Ishiguro N
    Hum Pathol; 2019 Feb; 84():155-163. PubMed ID: 30292627
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunohistochemical staining with non-phospho β-catenin as a diagnostic and prognostic tool of COX-2 inhibitor therapy for patients with extra-peritoneal desmoid-type fibromatosis.
    Sakai T; Nishida Y; Hamada S; Koike H; Ikuta K; Ota T; Ishiguro N
    Diagn Pathol; 2017 Aug; 12(1):66. PubMed ID: 28851389
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinicopathological features of 70 desmoid-type fibromatoses confirmed by β-catenin immunohistochemical staining and CTNNB1 mutation analysis.
    An J; Woo HY; Lee Y; Kim HS; Jeong J; Kim SK
    PLoS One; 2021; 16(4):e0250619. PubMed ID: 33914771
    [TBL] [Abstract][Full Text] [Related]  

  • 4. β-Catenin in desmoid-type fibromatosis: deep insights into the role of T41A and S45F mutations on protein structure and gene expression.
    Colombo C; Belfiore A; Paielli N; De Cecco L; Canevari S; Laurini E; Fermeglia M; Pricl S; Verderio P; Bottelli S; Fiore M; Stacchiotti S; Palassini E; Gronchi A; Pilotti S; Perrone F
    Mol Oncol; 2017 Nov; 11(11):1495-1507. PubMed ID: 28627792
    [TBL] [Abstract][Full Text] [Related]  

  • 5. β-catenin (CTNNB1) mutations and clinicopathological features of mesenteric desmoid-type fibromatosis.
    Huss S; Nehles J; Binot E; Wardelmann E; Mittler J; Kleine MA; Künstlinger H; Hartmann W; Hohenberger P; Merkelbach-Bruse S; Buettner R; Schildhaus HU
    Histopathology; 2013 Jan; 62(2):294-304. PubMed ID: 23020601
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Droplet Digital PCR (ddPCR) as a Novel Technology in Detecting CTNNB1 Mutations in Desmoid Fibromatosis.
    Gandhi J; Kao E; Wu Y; Mantilla JG; Ricciotti RW; Bandhlish A; Liu YJ; Chen EY
    Appl Immunohistochem Mol Morphol; 2022 Nov-Dec 01; 30(10):662-667. PubMed ID: 36227098
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Radiation-induced Sarcomas Occurring in Desmoid-type Fibromatosis Are Not Always Derived From the Primary Tumor.
    Verschoor AJ; Cleton-Jansen AM; Wijers-Koster P; Coffin CM; Lazar AJ; Nout RA; Rubin BP; Gelderblom H; Bovée JV
    Am J Surg Pathol; 2015 Dec; 39(12):1701-7. PubMed ID: 26414222
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CTNNB1 S45F mutation predicts poor efficacy of meloxicam treatment for desmoid tumors: a pilot study.
    Hamada S; Futamura N; Ikuta K; Urakawa H; Kozawa E; Ishiguro N; Nishida Y
    PLoS One; 2014; 9(5):e96391. PubMed ID: 24788118
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A comparison of the usefulness of nuclear beta-catenin in the diagnosis of desmoid-type fibromatosis among commonly used anti-beta-catenin antibodies.
    Yamada Y; Hirata M; Sakamoto A; Noguchi T; Ito K; Nishida Y; Matsuda S; Haga H
    Pathol Int; 2021 Jun; 71(6):392-399. PubMed ID: 33788979
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characteristics of cultured desmoid cells with different CTNNB1 mutation status.
    Hamada S; Urakawa H; Kozawa E; Arai E; Ikuta K; Sakai T; Ishiguro N; Nishida Y
    Cancer Med; 2016 Feb; 5(2):352-60. PubMed ID: 26686699
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lower Rate of CTNNB1 Mutations and Higher Rate of APC Mutations in Desmoid Fibromatosis of the Breast: A Series of 134 Tumors.
    Norkowski E; Masliah-Planchon J; Le Guellec S; Trassard M; Courrèges JB; Charron-Barra C; Terrier P; Bonvalot S; Coindre JM; Laé M
    Am J Surg Pathol; 2020 Sep; 44(9):1266-1273. PubMed ID: 32590455
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Detection of beta-catenin mutations in paraffin-embedded sporadic desmoid-type fibromatosis by mutation-specific restriction enzyme digestion (MSRED): an ancillary diagnostic tool.
    Amary MF; Pauwels P; Meulemans E; Roemen GM; Islam L; Idowu B; Bousdras K; Diss TC; O'Donnell P; Flanagan AM
    Am J Surg Pathol; 2007 Sep; 31(9):1299-309. PubMed ID: 17721184
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Correlation of CTNNB1 Mutation Status with Progression Arrest Rate in RECIST Progressive Desmoid-Type Fibromatosis Treated with Imatinib: Translational Research Results from a Phase 2 Study of the German Interdisciplinary Sarcoma Group (GISG-01).
    Kasper B; Gruenwald V; Reichardt P; Bauer S; Hohenberger P; Haller F
    Ann Surg Oncol; 2016 Jun; 23(6):1924-7. PubMed ID: 26861905
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Wnt targets genes are not differentially expressed in desmoid tumors bearing different activating β-catenin mutations.
    Timbergen MJM; Janssen ML; Verhoef C; Grünhagen DJ; Chibon F; Smid M; Sleijfer S; Wiemer EAC
    Eur J Surg Oncol; 2019 Apr; 45(4):691-698. PubMed ID: 30528042
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CTNNB1 Mutations and Estrogen Receptor Expression in Neuromuscular Choristoma and Its Associated Fibromatosis.
    Carter JM; Howe BM; Hawse JR; Giannini C; Spinner RJ; Fritchie KJ
    Am J Surg Pathol; 2016 Oct; 40(10):1368-74. PubMed ID: 27259010
    [TBL] [Abstract][Full Text] [Related]  

  • 16. β-Catenin mutation status and outcomes in sporadic desmoid tumors.
    Mullen JT; DeLaney TF; Rosenberg AE; Le L; Iafrate AJ; Kobayashi W; Szymonifka J; Yeap BY; Chen YL; Harmon DC; Choy E; Yoon SS; Raskin KA; Hornicek FJ; Nielsen GP
    Oncologist; 2013; 18(9):1043-9. PubMed ID: 23960186
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunohistochemical and Molecular Analyses Focusing on Mesenchymal Cells in Papillary Thyroid Carcinoma with Desmoid-Type Fibromatosis.
    Takada N; Mussazhanova Z; Hirokawa M; Nakashima M; Miyauchi A
    Pathobiology; 2018; 85(5-6):300-303. PubMed ID: 30223266
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of Familial Adenomatous Polyposis carriers among children with desmoid tumours.
    Kattentidt Mouravieva AA; Geurts-Giele IR; de Krijger RR; van Noesel MM; van de Ven CP; van den Ouweland AM; Kromosoeto JN; Dinjens WN; Dubbink HJ; Smits R; Wagner A
    Eur J Cancer; 2012 Aug; 48(12):1867-74. PubMed ID: 22305464
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Is mutation analysis of β-catenin useful for the diagnosis of desmoid-type fibromatosis? A systematic review.
    Sakai T; Hamada S; Koike H; Shimizu K; Yoshida M; Nishida Y
    Jpn J Clin Oncol; 2020 Sep; 50(9):1037-1042. PubMed ID: 32533146
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CTNNB1 genotyping and APC screening in pediatric desmoid tumors: a proposed algorithm.
    Wang WL; Nero C; Pappo A; Lev D; Lazar AJ; López-Terrada D
    Pediatr Dev Pathol; 2012; 15(5):361-7. PubMed ID: 22372443
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.